Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: Feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review

Annals of Oncology

Volumn 20, Issue 8, 2009, Pages 1387-1396

  Le Scodan, R ^a   Mornex, Francoise ^a   Girard, N ^a   Mercier, C ^a   Valette, P J ^b   Ychou, M ^c   Bibeau, F ^c   Roy, P ^a   Scoazec, J Y ^b   Partensky, C ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

Chemoradiation; Histopathological response; Neoadjuvant treatment; Pancreatic adenocarcinoma

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; MALE; NAUSEA AND VOMITING; NEUROTOXICITY; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PERITONEUM METASTASIS; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SKIN TOXICITY; STOMATITIS; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; CLINICAL TRIAL; FEASIBILITY STUDY; MIDDLE AGED; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 69449103331     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp015     Document Type: Article

References (52)

1. Bramhall SR, Allum WH, Jones AG et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study. Br J Surg 1985; 82: 111-115.
2. Yeo CJ, Abrams RA, Grochow LB et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-633.
3. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751-755.
4. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
5. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297(3): 267-277.
6. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698-703.
7. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
8. Ahmad NA, Lewis JD, Ginsberg GG et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 2001; 96: 2609-2615.
9. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
10. Mehta VK, Fisher GA, Ford JM et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000; 48: 1483-1487.
11. Corsini MM, Miller RC, Haddock MG et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol 2008; 26(21): 3511-3516.
12. Herman JM, Swartz MJ, Hsu CC et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26(21): 3503-3510.
13. Mornex F, Chauffert B. Concomitant chemoradiation in the management of exocrine pancreatic and gastric adenocarcinoma. Concomitant chemoradiation. Paris: Elsevier 1999; 139-148.
14. Spitz FR, Abbruzzese JL, Lee JE et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15: 928-937.
15. Willett CG, Lewandrowski K, Warshaw AL et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217: 144-148.
16. Benassai G, Mastrorilli M, Quarto G et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000; 73: 212-218.
17. Luttges J, Vogel I, Menke M et al. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch 1998; 433: 237-242.
18. Millikan KW, Deziel DJ, Silverstein JC et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65: 618-623.
19. Neoptolemos JP, Stocken DD, Dunn JA et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758-768.
20. Pingpank JF, Hoffman JP, Ross EA et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001; 5(2): 121-130.
21. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782.
22. Greene FL, Page DL, Felming ID et al. AJCC Cancer Staging Manual, 6th edition. New York: Springer-Verlag 2002; 157-164.
23. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
24. Trotti AD, Colevas AD, Setser A et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
25. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
26. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization 1979. Offset Publication No. 48.
27. Ishikawa O, Ohhigashi H, Teshima T et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol 1989; 40: 143-151.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
29. Mornex F, Girard N, Scoazec JY et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracile and cisplatin in potentially resectable pancreatic carcinoma: The French SFRO-FFCD 97-04 phase II trial. Int J Radiat Oncol Biol Phys 2006; 65(5): 1471-1478.
30. Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335-1339.
31. Yeung RS, Weese JL, Hoffman JP et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 1993; 72: 2124-2133.
32. Pisters PW, Abbruzzese JL, Janjan NA et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16: 3843-3850.
33. Hoffman JP, Lipsitz S, Pisansky T et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 317-323.
34. White RR, Hurwitz HI, Morse MA et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001; 8: 758-765.
35. Pisters PW, Wolff RA, Janjan NA et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002; 20: 2537-2544.
36. Moutardier V, Magnin V, Turrini O et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2004; 60: 437-443.
37. Joensuu TK, Kiviluoto T, Kärkkäinen P et al. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys Oct 1; 60(2): 444-452.
38. Talamonti MS, Small W Jr, Mulcahy MF et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006; 13(2): 150-158.
39. Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26(21): 3496-502.
40. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26(21): 3487-3495.
41. Snady H, Bruckner H, Cooperman A et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000; 89: 314-327.
42. Ishikawa O, Ohigashi H, Imaoka S et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch Surg 1994; 129: 1075-1080.
43. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721-731.
44. Wagner M, Redaelli C, Lietz M et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91(5): 586-594.
45. White RR, Xie HB, Gottfried MR et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 2005; 12(3): 214-221.
46. Staley CA, Lee JE, Cleary KR et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171(1): 118-124.
47. Breslin TM, Hess KR, Harbison DB et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol 2001; 8(2): 123-132.
48. Sasson AR, Wetherington RW, Hoffman JP et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Analysis of histopathology and outcome. Int J Gastrointest Cancer 2003; 34(2-3): 121-128.
49. White RR, Kattan MW, Haney JC et al. Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. Ann Surg Oncol 2006; 13: 1485-1492.
50. Wayne JD, Abdalla EK, Wolff RA et al. Localized adenocarcinoma of the pancreas: The rationale for preoperative chemoradiation. Oncologist 2002; 7: 34-45.
51. Mornex F, Girard N, Partensky C et al. Radiochemotherapy in the management of pancreatic cancer - part 1 neoadjuvant treatment. Semin Radiat Oncol 2005; 15: 226-234.
52. Crane CH, Varadhachary G, Wolff RA et al. The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20(2): 365-382.